Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Review

Patient reported outcome measures in rare diseases: a narrative review

Authors: Anita Slade, Fatima Isa, Derek Kyte, Tanya Pankhurst, Larissa Kerecuk, James Ferguson, Graham Lipkin, Melanie Calvert

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Rare diseases can lead to a significant reduction in quality of life for patients and their families. Ensuring the patients voice is central to clinical decision making is key to delivering, evaluating and understanding the efficacy of therapeutic interventions. Patient reported outcome measures (PROMs) are used to capture the patient’s views about their health status and facilitate our understanding of the impact of these diseases and their treatments on patient’s quality of life and symptoms.

Main text

This review explores some of the current issues around the utilisation of PROMs in rare diseases, including small patient populations and dearth of valid PROMs. Difficulties in validating new or current PROMs for use in clinical trials and research are discussed. The review highlights potential solutions for some of the issues outlined in the review and the implementation of PROMs in research and clinical practice are discussed.

Conclusion

Patient input throughout the development of PROMs including qualitative research is essential to ensure that outcomes that matter to people living with rare disease are appropriately captured. Given the large number of rare diseases, small numbers of patients living with each condition and the cost of instrument development, creative and pragmatic solutions to PROM development and use may be necessary. Solutions include qualitative interviews, modern psychometrics and resources such as item banking and computer adaptive testing. Use of PROMs in rare disease research and clinical practice offers the potential to improve patient care and clinical outcomes.
Literature
1.
2.
3.
4.
EMA. Orphan medicines in the EU-leaving no patient behind. 2017. Accessed 8 Jan 2018.
5.
Johansen H, Dammann B, Andresen I-L, Fagerland MW. Health-related quality of life for children with rare diagnoses, their parents’ satisfaction with life and the association between the two. Health Qual Life Outcomes. 2013;11:152.CrossRefPubMedPubMedCentral
6.
Schalet BD, Pilkonis PA, Yu L, Dodds N, Johnston KL, Yount S, Riley W, Cella D. Clinical validity of PROMIS depression, anxiety, and anger across diverse clinical samples. J Clin Epidemiol. 2016;73:119–27.CrossRefPubMedPubMedCentral
7.
Spillmann RC, McConkie-Rosell A, Pena L, Jiang Y-H, Schoch K, Walley N, Sanders C, Sullivan J, Hooper SR, Shashi V. A window into living with an undiagnosed disease: illness narratives from the undiagnosed diseases network. Orphanet J Rare Dis. 2017;12:71.CrossRefPubMedPubMedCentral
8.
9.
Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119:964–79.CrossRefPubMed
10.
Silibello G, Vizziello P, Gallucci M, Selicorni A, Milani D, Ajmone PF, Rigamonti C, De Stefano S, Bedeschi MF, Lalatta F. Daily life changes and adaptations investigated in 154 families with a child suffering from a rare disability at a public Centre for rare diseases in northern Italy. Ital J Pediatr. 2016;42:76.CrossRefPubMedPubMedCentral
11.
Dellve L, Samuelsson L, Tallborn A, Fasth A, Hallberg LR. Stress and well-being among parents of children with rare diseases: a prospective intervention study. J Adv Nurs. 2006;53:392–402.CrossRefPubMed
12.
Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-Reported Outcome and Observer-reported outcome assessment in rare disease clinical trials - emerging good practices: an ISPOR COA emerging good practices report. Value Health. 2017;7:838–55.CrossRef
13.
14.
Rotenstein LS, Huckman RS, Wagle NW. Making patients and doctors happier — the potential of patient-reported outcomes. N Engl J Med. 2017;377:1309–12.CrossRefPubMed
15.
16.
Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, Liberty J. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015;26:1846–58.CrossRefPubMed
17.
Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use, 4th edn. Oxford: Oxford University Press; 2008.CrossRef
18.
Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L, Lampe C. Burden of disease in patients with Morquio a syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis. 2014;9:32.CrossRefPubMedPubMedCentral
19.
Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, O'Neill R, Kennedy DL. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10:S125–S37.CrossRefPubMed
20.
Basch E, Geoghegan C, Coons S, et al. Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the food and drug administration, and the patient. JAMA Oncol. 2015;1:375–9.CrossRefPubMed
21.
22.
23.
Calvert M, Kyte D, Duffy H, Gheorghe A, Mercieca-Bebber R, Ives J, Draper H, Brundage M, Blazeby J, King M. Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. PLoS One. 2014;9:e110216.CrossRefPubMedPubMedCentral
24.
25.
26.
Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999;37:126–39.CrossRefPubMed
27.
Ravens-Sieberer U, Herdman M, Devine J, Otto C, Bullinger M, Rose M, Klasen F. The European KIDSCREEN approach to measure quality of life and well-being in children: development, current application, and future advances. Qual Life Res. 2014;23:791–803.CrossRefPubMed
28.
Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, Benmedjahed K, Regnault A. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet J Rare Dis. 2015;10:80.CrossRefPubMedPubMedCentral
29.
Regnault A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K, Bosch AM. Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients’ and parents’ quality of life: the phenylketonuria – quality of life (PKU-QOL) questionnaires. Orphanet J Rare Dis. 2015;10:59.CrossRefPubMedPubMedCentral
30.
Barry JA, Folkard A, Denniston AK, Moran E, Ayliffe W. Development and validation of quality-of-life questionnaires for birdshot Chorioretinopathy. Ophthalmology. 2014;121:1488–9. e2CrossRefPubMed
31.
Zhang H, Wang L, Quan M, Huang J, Wu P, Lu Q, Fang Y. Health-related quality of life in children with chronic immune thrombocytopenia in China. Health Qual Life Outcomes. 2016;14:45.CrossRefPubMedPubMedCentral
32.
Ramaswami U, Stull DE, Parini R, Pintos-Morell G, Whybra C, Kalkum G, Rohrbach M, Raluy-Callado M, Beck M, Chen W-H, et al. Measuring patient experiences in Fabry disease: validation of the Fabry-specific pediatric health and pain questionnaire (FPHPQ). Health Qual Life Outcomes. 2012;10:116.CrossRefPubMedPubMedCentral
33.
34.
Arends M, Hollak CEM, Biegstraaten M. Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis. 2015;10:77.CrossRefPubMedPubMedCentral
35.
Hjollund INH, Larsen PL, Biering K, Johnsen PS, Riiskjær E, Schougaard ML. Use of patient-reported outcome (PRO) measures at group and patient levels: experiences from the generic integrated PRO system, WestChronic. Interact J Med Res. 2014;3:e5.CrossRefPubMedPubMedCentral
36.
Jensen RE, Rothrock NE, DeWitt EM, Spiegel B, Tucker CA, Crane HM, Forrest CB, Patrick DL, Fredericksen R, Shulman LM, et al. The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care. Med Care. 2015;53:153–9.CrossRefPubMedPubMedCentral
37.
Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, et al. Symptom monitoring with patient-reported outcomes during routine Cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34:557–65.CrossRefPubMed
38.
Snyder CF, Aaronson NK. Use of patient-reported outcomes in clinical practice. Lancet. 2009;374:369–70.CrossRefPubMed
39.
Luckett T, Butow PN, King MT. Improving patient outcomes through the routine use of patient-reported data in cancer clinics: future directions. Psychooncology. 2009;18:1129–38.CrossRefPubMed
40.
Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624–32.CrossRefPubMedPubMedCentral
41.
Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25:5121–7.CrossRefPubMed
42.
Trujillano D, Oprea GE, Schmitz Y, Bertoli-Avella AM, Abou Jamra R, Rolfs A. A comprehensive global genotype–phenotype database for rare diseases. Mol Genet Genomic Med. 2017;5:66–75.CrossRefPubMed
43.
Morel T, Cano SJ. Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J Rare Dis. 2017;12:171.CrossRefPubMedPubMedCentral
44.
45.
Newman SC, Bland RC, Orn H. A comparison of methods of scoring the general health questionnaire. Compr Psychiatry. 1988;29:402–8.
46.
47.
48.
Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, et al. The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33:1199–203.CrossRefPubMedPubMedCentral
49.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, et al. A double-blind placebo-controlled trial of Ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.CrossRefPubMedPubMedCentral
50.
Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, et al. Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. Cancer. 2011;117:4869–77.CrossRefPubMedPubMedCentral
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
Devlin NJ, Parkin D, Browne J. Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Econ. 2010;19:886–905.CrossRefPubMed
61.
62.
Calvert M, Thwaites R, Kyte D, Devlin N. Putting patient-reported outcomes on the ‘Big data road Map’. J R Soc Med. 2015;108:299–303.CrossRefPubMed
63.
Kyte D, Cockwell P, Lencioni M, Skrybant M, von Hildebrand M, Price G, Squire K, Webb S, Brookes O, Fanning H, et al. Reflections on the national patient-reported outcome measures (PROMs) programme: where do we go from here? J R Soc Med. 2016;109(12):441–5.CrossRefPubMed
64.
65.
66.
67.
Prinsen CA, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, Williamson PR, Terwee CB. How to select outcome measurement instruments for outcomes included in a “Core outcome set” - a practical guideline. Trials. 2016;17:449.CrossRefPubMedPubMedCentral
68.
Terwee CB, Mokkink LB, Knol DL, Ostelo RWJG, Bouter LM, de Vet HCW. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res. 2012;21:651–7.CrossRefPubMed
69.
Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, Bouter LM, De Vet HCW. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol. 2010;10:22.CrossRefPubMedPubMedCentral
70.
Isa F, Turner G, Kyte D, Slade A, Pankhurst T, Kerecuk L, Keeley T, Ferguson J, Calvert M. Patient reported outcome measures used in patients with primary sclerosing cholangistis: systematic review. Copenhagen: ISOQOL; 2016.
71.
Younossi ZM, Afendy A, Stepanova M, Racila A, Nader F, Gomel R, Safer R, Lenderking WR, Skalicky A, Kleinman L, Myers RP, Subramanian GM, McHutchison JG, Levy C, Bowlus CL, Kowdley K, Muir AJ. Development and Validation of a Primary Sclerosing Cholangitis-Specific Patient-Reported Outcomes Instrument: The PSC PRO. Hepatology. 2018. Accepted Author Manuscript. https://​doi.​org/​10.​1002/​hep.​29664.
72.
73.
Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, Ader D, Fries JF, Bruce B, Rose M. The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Med Care. 2007;45:S3–S11.CrossRefPubMedPubMedCentral
74.
Bevans M, Ross A, Cella D. Patient-reported outcomes measurement information system (PROMIS(®)): efficient, standardized tools to measure self-reported health and quality of life. Nurs Outlook. 2014;62:339–45.CrossRefPubMedPubMedCentral
75.
van der Beek NAME, Hagemans MLC, van der Ploeg AT, van Doorn PA, Merkies ISJ. The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul Disord. 2013;23:256–64.CrossRefPubMed
76.
Mattera MS, Kaplan FS, Pignolo RJ, Grogan D, Revicki DA. Patient-reported physical function outcome measure for adults with Fibrodysplasia Ossificans Progressiva: intelligent test design based on Promis item banks. Value Health. 2015;18:A165.CrossRef
77.
Hermans MCE, Hoeijmakers JGJ, Faber CG, Merkies ISJ. Reconstructing the Rasch-built myotonic dystrophy type 1 activity and participation scale. PLoS One. 2015;10:e0139944.CrossRefPubMedPubMedCentral
78.
Wolfe E. Equating and item banking with the Rasch model. J Appl Meas. 2000;1:409.PubMed
79.
Pallant JF, Tennant A. An introduction to the Rasch measurement model: an example using the hospital anxiety and depression scale (HADS). Br J Clin Psychol. 2007;46:1–18.CrossRefPubMed
80.
Du Y, Yates F. When to adjust for differential item functioning. In: Rasch Measurement Transactions vol 9; 1995. p. 414.
81.
Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health. 2005;8:94–104.CrossRefPubMed
82.
Wild D, Eremenco S, Mear I, Martin M, Houchin C, Gawlicki M, Hareendran A, Wiklund I, Chong LY, von Maltzahn R, et al. Multinational trials—recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR patient-reported outcomes translation and linguistic validation good research practices task force report. Value Health. 2009;12:430–40.CrossRefPubMed
83.
Regnault A, Herdman M. Using quantitative methods within the universalist model framework to explore the cross-cultural equivalence of patient-reported outcome instruments. Qual Life Res. 2015;24:115–24.CrossRefPubMed
84.
Tennant A, Penta M, Tesio L, Grimby G, Thonnard JL, Slade A, Lawton G, Simone A, Carter J, Lundgren-Nilsson A, et al. Assessing and adjusting for cross-cultural validity of impairment and activity limitation scales through differential item functioning within the framework of the Rasch model - The PRO-ESOR project. Med Care. 2004;42:37–48.CrossRef
85.
Cano SJ, Mayhew A, Glanzman AM, Krosschell KJ, Swoboda KJ, Main M, Steffensen BF, BÉRard C, Girardot F, Payan CA, et al. Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle Nerve. 2014;49:422–30.CrossRefPubMed
86.
Aiyegbusi OL, Kyte D, Cockwell P, Marshall T, Dutton M, Slade A, Marklew N, Price G, Verdi R, Waters J, et al. Using patient-reported outcome measures (PROMs) to promote quality of care and safety in the management of patients with advanced chronic kidney disease (PRO-trACK project): a mixed-methods project protocol. BMJ Open. 2017;7:e016687.CrossRefPubMedPubMedCentral
87.
Zhu X, Cahan A. Wearable technologies and telehealth in Care Management for Chronic Illness. In: Weaver CA, Ball MJ, Kim GR, Kiel JM, editors. Healthcare Information management systems: cases, strategies, and solutions. Cham: springer international publishing; 2016. p. 375–98.CrossRef
88.
89.
Metadata
Title
Patient reported outcome measures in rare diseases: a narrative review
Authors
Anita Slade
Fatima Isa
Derek Kyte
Tanya Pankhurst
Larissa Kerecuk
James Ferguson
Graham Lipkin
Melanie Calvert
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0810-x

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue

Review

Acid ceramidase deficiency: Farber disease and SMA-PME

Research

Detection rate of causal variants in severe childhood epilepsy is highest in patients with seizure onset within the first four weeks of life

Position statement

A perspective on “cure” for Rett syndrome

Research

PhenoDis: a comprehensive database for phenotypic characterization of rare cardiac diseases

Research

Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications

Research

Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect